Elisabet Lidbrink

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

Linda S. Lindström, Eva Karlsson, Ulla Wilking et al. · Journal of Clinical Oncology · 2012 · 517 citations

Hormonal Receptors, Breast Oncology, Progesterone Receptor +15

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

Jonas Bergh, Tom Wiklund, Björn Erikstein et al. · The Lancet · 2000 · 342 citations

Breast Oncology, Oncology, High-risk Breast Cancer +7

FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer

Jonas Bergh, Per‐Ebbe Jönsson, Elisabet Lidbrink et al. · Journal of Clinical Oncology · 2012 · 264 citations

Randomized study of mammography screening — preliminary report on mortality in the stockholm trial

Jan Frisell, Gunnar Eklund, Lennart Hellström et al. · Breast Cancer Research and Treatment · 1991 · 262 citations

Stockholm Trial, Cancer Detection, Cancer Screening +9

Followup after 11 years – update of mortality results in the Stockholm mammographic screening trial

Jan Frisell, Elisabet Lidbrink, Lars Hellström et al. · Breast Cancer Research and Treatment · 1997 · 223 citations

Cancer Detection, Cancer Screening, Medicine +7